Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Trading 24.6% Higher – Should You Buy?

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF)’s stock price traded up 24.6% during mid-day trading on Tuesday . The company traded as high as $3.65 and last traded at $3.65. 200 shares changed hands during mid-day trading, a decline of 53% from the average session volume of 425 shares. The stock had previously closed at $2.93.

Hansa Biopharma AB (publ) Trading Up 24.6 %

The firm has a fifty day moving average of $2.93 and a 200-day moving average of $2.93.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.